Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03961360 · ClinicalTrials.gov registry record · Phase 2
Effectiveness of Higher Aspirin Dosing for Prevention of Preeclampsia in High Risk Obese Gravida
A Phase 2 study, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- Phase 2
- Development phase
- 220
- Enrollment target
NCT03961360 is a Phase 2 study that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 220 participants.
The verdict
NCT03961360, a Phase 2 study, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 220 participants
- Enrollment target
Study Summary
To compare the incidence of preeclampsia in obese pregnant women (BMI greater than 30) with a singleton gestation at less than 20 weeks and either a history of preeclampsia in a prior pregnancy or stage I hypertension or pre-gestational diabetes who are randomized to either 81mg/day aspirin or 162mg/day aspirin.
Interventions
- DRUG Aspirin 162 mg
- DRUG Aspirin 81 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2019-05-06 |
| Est. Completion | 2023-04-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03961360
The ClinicalTrials.gov registry entry for NCT03961360 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Aspirin 162 mg is the first listed.
NCT03961360 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03961360 about?
NCT03961360 is a clinical study titled "Effectiveness of Higher Aspirin Dosing for Prevention of Preeclampsia in High Risk Obese Gravida". To compare the incidence of preeclampsia in obese pregnant women (BMI greater than 30) with a singleton gestation at less than 20 weeks and either a history of preeclampsia in a prior pregnancy or stage I hypertension or pre-gestational diabetes who are randomized to either 81mg/day aspirin or 162mg...
What is the current status of trial NCT03961360?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 220 participants. The study started on 2019-05-06. Estimated completion is 2023-04-10.
What interventions are being tested in trial NCT03961360?
The interventions under investigation include: Aspirin 162 mg (DRUG), Aspirin 81 mg (DRUG).
Who is sponsoring clinical trial NCT03961360?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.